| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | barasertib | CTRPv2 | pan-cancer | AAC | 0.054 | 0.1 |
| mRNA | GDC-0941 | gCSI | pan-cancer | AAC | -0.11 | 0.1 |
| mRNA | BRD-K48477130 | CTRPv2 | pan-cancer | AAC | -0.092 | 0.1 |
| mRNA | Compound 7d-cis | CTRPv2 | pan-cancer | AAC | 0.061 | 0.1 |
| mRNA | AT13387 | CTRPv2 | pan-cancer | AAC | 0.075 | 0.1 |
| mRNA | L-685458 | CCLE | pan-cancer | AAC | 0.074 | 0.1 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.053 | 0.1 |
| mRNA | MK 1775 | CTRPv2 | pan-cancer | AAC | 0.055 | 0.1 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | -0.058 | 0.1 |
| mRNA | Epothilone B | FIMM | pan-cancer | AAC | 0.45 | 0.1 |